Niraparib : New treatment for new diagnosed Ovarian Cancer

A landmark study presented at ESMO congress at Barcelona shows significant benefits for maintenance treatment with the drug Niraparib.

Niraparib is likely to become a standard treatment in a much more widely group of advanced ovarian cancer patients.

Many clinicians will be weighing up Niraparib Vs Olaparib in Some patients and Niraparib vs Bevacizumab in other groups of patients.


1. Niraparib Prolongs PFS in Patients with Newly Diagnosed Advanced Ovarian Cancer. ESMO press release.

Acknowledgement: Copyright of Slides: Authors and ESMO